Abstract
Diet-microbiota related inflammatory conditions such as obesity, autoimmune type 1 diabetes (T1D), type 2 diabetes (T2D), cardiovascular disease (CVD) and gut infections have become a stigma in Western societies and developing nations. This book chapter examines the most relevant pre-clinical and clinical studies about diet-gut microbiota approaches as an alternative therapy for diabetes. We also discuss what we and others have extensively investigated- the power of dietary short-chain fatty acids (SCFAs) technology that naturally targets the gut microbiota as an alternative method to prevent and treat diabetes and its related complications.
| Original language | English |
|---|---|
| Title of host publication | Diabetes |
| Subtitle of host publication | from Research to Clinical Practice |
| Editors | Md. Shahidul Islam |
| Place of Publication | Switzerland |
| Publisher | Springer |
| Pages | 499-519 |
| Number of pages | 21 |
| Volume | 4 |
| ISBN (Electronic) | 9783030510893 |
| ISBN (Print) | 9783030510886 |
| DOIs | |
| Publication status | Published - 2021 |
Publication series
| Name | Advances in Experimental Medicine and Biology |
|---|---|
| Volume | 1307 |
| ISSN (Print) | 0065-2598 |
| ISSN (Electronic) | 2214-8019 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Clinical trials
- Diet
- Microbiota
- SCFAs
- T1D
- T2D
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver